ARS Pharmaceuticals, Inc (SPRY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $360.90M
Last updated: Nov 17, 2026 at 4:15 PM ET
ARS Pharmaceuticals, Inc (SPRY) Stock Chart
ARS Pharmaceuticals (SPRY) has a latest price of $3.65 on Nov 17, 2026, 72.2% below its 52-week high of $13.15. Its price fell 55.5% over the past 12 months. The month-end price fell 60.8% over the 5 years through Oct 2026, a compound annual decline of 17.1%.
Price Chart
From Dec 2020 to Oct 2026, its highest month-end close was $48.06 in Feb 2021 and its lowest $3.11 in Apr 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart SPRY with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for SPRY.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 42.8%, and over 6 months it fell 49.1%. The month-end price fell 5.3% over the 3 years through Oct 2026, a compound annual decline of 1.8%.
| Period | Change |
|---|---|
| 1 month | -13.7% |
| 3 months | -42.8% |
| 6 months | -49.1% |
| 12 months | -55.5% |
| 12 months, with dividends | -55.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -5.3% | -1.8% |
| 5 years | -60.8% | -17.1% |
Price by Year
Its best calendar year was 2024, when the price rose 92.5%, and its weakest was 2021, when it fell 85.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.38 | -71.0% |
| 2025 | $11.65 | +10.4% |
| 2024 | $10.55 | +92.5% |
| 2023 | $5.48 | -35.8% |
| 2022 | $8.53 | +28.1% |
| 2021 | $6.66 | -85.6% |
Trading Range
The price is 8.8% below its 50-day average of $4.00 and 47.6% below its 200-day average of $6.97.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.65 | |
| 52-week high | $13.15 | -72.2% |
| 52-week low | $2.44 | +49.6% |
| 50-day average | $4.00 | -8.8% |
| 200-day average | $6.97 | -47.6% |
Price Risk
Over 3 years, its largest fall from a peak was 85.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.80 |
| Largest fall, 1 year | -79.7% |
| Largest fall, 3 years | -85.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About SPRY
What is SPRY's 1-year price change?
ARS Pharmaceuticals's price fell 55.5% over the past 12 months. With dividends included, the 12-month total return was -55.5%.
What is SPRY's 5-year price change?
ARS Pharmaceuticals's month-end price fell 60.8% over the 5 years through Oct 2026, a compound annual decline of 17.1%. These figures leave out dividends.
What is SPRY's 52-week high and low?
ARS Pharmaceuticals's 52-week high is $13.15 and its 52-week low is $2.44. Its latest price of $3.65 on Nov 17, 2026 is 72.2% below the high.
What is SPRY's beta?
ARS Pharmaceuticals's 1-year beta against the S&P 500 is 1.80, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 79.7%.
Is the SPRY chart free?
Yes. Advanced Charting for SPRY is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
SPRY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors